Literature DB >> 19921190

Cytogenetic features and prognosis analysis in Chinese patients with myelodysplastic syndrome: a multicenter study.

Hong Wang1, Xiaoqin Wang, XiaoPing Xu, GuoWei Lin.   

Abstract

It has been suggested that Asian and Western myelodysplastic syndrome (MDS) patients have different cytogenetic and prognostic features. In this study, we retrospectively analyzed clinical and cytogenetic data from 435 Chinese adult primary MDS patients. In addition, we evaluated the prognostic value of the World Health Organization classification as well as six prognostic scoring systems in these patients. The median follow-up time was 25.1 months (5.5-53.2). Of the 435 patients, 186 (42.8%) had died and 40 (9.2%) had progressed to acute myeloid leukemia. Multivariate analysis identified older age, higher percent of marrow blasts, and poor-risk IPSS cytogenetics as characteristics associated with worse survival and higher risk of leukemia transformation. Low platelets, hemoglobin, and mean corpuscular volume were independent factors associated only with worse survival. Among the 424 patients in whom the results of cytogenetic analyses were available, 164 (38.7%) showed karyotypic abnormalities. Incidence of trisomy 8 was common but sole del(5q) was rare in Chinese MDS patients. For predicting survival, most scoring systems were meaningful for stratifying patients into different subgroups, with the exception of the WPSS scoring system. For predicting leukemia evolution, the Spanish scoring system was most effective. Patients with RAEB-2 showed different prognoses from those with RAEB-1. However, there was no significant difference in prognoses between patients with refractory cytopenia with multilineage dysplasia (RCMD) from RA or RARS. In summary, this analysis indicated the presence of a different cytogenetic pattern as well as prognostic features in Chinese MDS patients.

Entities:  

Mesh:

Year:  2009        PMID: 19921190     DOI: 10.1007/s00277-009-0861-0

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  6 in total

1.  The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromes.

Authors:  Michaela Cada; Catherin I Segbefia; Robert Klaassen; Conrad V Fernandez; Rochelle A Yanofsky; John Wu; Yves Pastore; Mariana Silva; Jeffrey H Lipton; Josee Brossard; Bruno Michon; Sharon Abish; MacGregor Steele; Roona Sinha; Mark Belletrutti; Vicky Breakey; Lawrence Jardine; Lisa Goodyear; Lillian Sung; Mary Shago; Joseph Beyene; Preeti Sharma; Bozana Zlateska; Yigal Dror
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

2.  11q23 abnormalities in adult Chinese patients with hematological malignancies.

Authors:  Xiaoli Zhao; Shuang Li; Nianyi Li; Rong Fan; Guowei Lin; Xiaoqin Wang
Journal:  Med Oncol       Date:  2014-07-10       Impact factor: 3.064

3.  Acquired aplastic anemia associated with trisomy eight converting into acute myeloid leukemia.

Authors:  Sumit Grover; Amit Kumar Dhiman; Bhavna Garg; Neena Sood; Vikram Narang
Journal:  J Lab Physicians       Date:  2017 Jul-Sep

4.  Cytogenetic characteristics of 665 patients with myelodysplastic syndrome in China: A single-center report.

Authors:  Xueying Wang; Weiyi Liu; Mingjing Wang; Teng Fan; Yumeng Li; Xiaoqing Guo; Xiupeng Yang; Hongzhi Wang; Haiyan Xiao; Shanshan Zhang; Richeng Quan; Chi Liu; Xudong Tang; Yan Lv; Zhuo Chen; Liu Li; Yonggang Xu; Rou Ma; Xiaomei Hu
Journal:  Oncol Lett       Date:  2020-12-17       Impact factor: 2.967

5.  Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes.

Authors:  Xuefen Yan; Lu Wang; Lingxu Jiang; Yingwan Luo; Peipei Lin; Wenli Yang; Yanling Ren; Liya Ma; Xinping Zhou; Chen Mei; Li Ye; Gaixiang Xu; Weilai Xu; Haiyang Yang; Chenxi Lu; Jie Jin; Hongyan Tong
Journal:  Cancer Med       Date:  2021-02-20       Impact factor: 4.452

Review 6.  Oral Arsenic-Containing Qinghuang Powder: A Potential Drug for Myelodysplastic Syndromes.

Authors:  Jing Ming; Wei-Yi Liu; Hai-Yan Xiao; Yong-Gang Xu; Rou Ma; Xiao-Mei Hu
Journal:  Chin J Integr Med       Date:  2020-03-07       Impact factor: 2.626

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.